Induction of labour

Active Ingredient: Dinoprostone

Indication for Dinoprostone

Population group: women, only adults (18 - 65 years old)
Therapeutic intent: Neo-adjuvant intent

Dinoprostone is indicated for the induction of labour, especially in patients with favourable induction features, when there are no foetal or maternal contra-indications.

For this indication, competent medicine agencies globally authorize below treatments:

3-6 mg in 1-2 divided doses

Route of admnistration

Endocervical

Defined daily dose

3 - 6 mg

Dosage regimen

From 3 To 6 mg once every day

Loading dose

3 mg

Detailed description

3 mg to be inserted high into the posterior fornix. 3 mg may be inserted after six to eight hours if labour is not established. Maximum dose 6 mg.

Dosage considerations

The tablets should be inserted high into the posterior fornix.

0.25-1.50 ug once

Route of admnistration

Intravenous

Defined daily dose

0.25 - 1.5 ug

Dosage regimen

From 0.25 To 1.5 ug once every day

Loading dose

0.25 ug

Detailed description

Directions for the Preparation of a Dilute Solution:

For use by IV drip (a drip set delivering 60 drops/per ml must be used) or constant rate infusion pump. Withdraw 0.75 ml from the ampoule using an aseptic technique and add to 500 ml sterile normal saline or 5% dextrose. Shake to ensure uniformity.

After dilution attach label provided. Use dilute solution within 24 hours of preparation and store in a refrigerator at 2-8°C.

The dose of dinoprostone used normally depends not only upon the indication but also on patient response.

The following is a guide to dosage:

Dilute with normal saline or 5% dextrose to produce a 1.5 micrograms/ml solution. The 1.5 micrograms/ml solution is infused at 0.25 micrograms/minute for 30 minutes and then maintained or increased. Cases of foetal death in utero may require higher doses. An initial rate of 0.5 micrograms/minute may be used with stepwise increases, at intervals of not less than one hour.

The appearance of foetal distress or uterine hypertonus requires cessation of therapy until the state returns to normal. The situation should be re-assessed and, if necessary, the infusion can be recommenced but at lower dosage rates, 50% of the last dose level used.

If no response is seen within the first 12-24 hours of treatment, the medication should be discontinued.

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.